131 related articles for article (PubMed ID: 20102031)
1. New oncology drugs and osteonecrosis of the jaw (ONJ).
Migliorati CA; Covington JS
J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
[No Abstract] [Full Text] [Related]
2. Osteonecrosis of the jaw and the role of macrophages.
Pazianas M
J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
[TBL] [Abstract][Full Text] [Related]
3. More about osteonecrosis.
Finkelman RD; Clemons M; Bouganim N
J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
[No Abstract] [Full Text] [Related]
4. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
[No Abstract] [Full Text] [Related]
5. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
[No Abstract] [Full Text] [Related]
7. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for bisphosphonate-related osteonecrosis of the jaws.
Fleisher KE; Glickman RS
J Oral Maxillofac Surg; 2011 Apr; 69(4):959; author reply 959-60. PubMed ID: 21440820
[No Abstract] [Full Text] [Related]
9. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
10. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?
Aragon-Ching JB; Dahut WL
Oncologist; 2008 Dec; 13(12):1314; author reply 1315. PubMed ID: 19088325
[No Abstract] [Full Text] [Related]
12. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
Wynn RL
Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
[No Abstract] [Full Text] [Related]
13. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw.
Reilly MM; Moore S
Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):39-41. PubMed ID: 18431898
[No Abstract] [Full Text] [Related]
15. Editorial: bisphosphonates.
Reid RJ
Aust Endod J; 2007 Aug; 33(2):53-4. PubMed ID: 17697244
[No Abstract] [Full Text] [Related]
16. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
[TBL] [Abstract][Full Text] [Related]
17. Denosumab-related osteonecrosis of the jaws.
Kyrgidis A; Toulis KA
Osteoporos Int; 2011 Jan; 22(1):369-70. PubMed ID: 20306021
[No Abstract] [Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.
Naik NH; Russo TA
Clin Infect Dis; 2009 Dec; 49(11):1729-32. PubMed ID: 19886792
[TBL] [Abstract][Full Text] [Related]
19. Intravenous bisphosphonate treatment and osteonecrosis of the jaw in patients with cancer: wide CIs, Yule-Simpson and King Kong effects, and no therapeutic outcomes.
Abraham I
J Clin Oncol; 2010 Mar; 28(9):e143-4; author reply e145-7. PubMed ID: 20159796
[No Abstract] [Full Text] [Related]
20. Jaw osteonecrosis related to bisphosphonates: a new concern for dentistry.
Geist RY; Geist JR; Aksu M
J Mich Dent Assoc; 2005 Nov; 87(11):40-2. PubMed ID: 16372547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
